Interesting stats , I like stats! So, now & again I like to dig into things.
Things people post, what, why & when.
no doubt, notable wins the award for most posts.
he has been around a long time. Huge % of his stuff is related to ONC. Very large % related to beiotech in general.
His points well taken....many biotechs with less on- the- go than Onc have been bought out for many billions.
To paraphrase his comments, Onc has huge potential, with the upcoming events.
FDA fast track, & potential for accelerated approval, for both MBc & pancreatic cancer.
myself? I certainly agree 100%, Onc is way under valued.
and there ihe the Buck Henry?
Only on the site since 2022. With over 200 posts to his name.
Zero of which with any data, Not able to counter anything, other than to insult others on here & the company. Today going as far as to say the site has become worthless.
Sadly the majority of worthless comments are from Bucky himself.
kind of self analysis, on his part , I guess.
So, saying that. What do we know about Onc & what do we not know?
First, Onc has been around a long time. Trials have come & gone. Some good , some bad.
Those why enjoy bashing mangement?
The lowest point was around 2017 , they were trading near .50 on the TSX & under $1, on the Nas.
Rsther than throw in the towel, Onc teamed up with Pfizer, Roche, & Incyte.
At the advice of the FDA, to identify biomarkers. Which alongside a subsidiary of Pfizer, using cutting edge DNA, identifiers, have come up with two indentafyable biomarkers.
Both of which are part of the request in font if FDA for a special phase 3 approval process.
With a simple blood draw, after 2 weeks they can know if Pelareorep is working or not. Thst is a huge trial & clinical advantage.
We don't know exactly when the FDA/ CGAR updates will be.
however indication point towards end of this month, before the next poster presentations.
Again, that date has not been stamped, other than the discussion at AGM/ fireside chat.
regardless of exact dates, what needs to be considered is the following:
CGAR, has publicly announced their support of the modified phase 3 trial.
That being cohort #1, of the Gobblet, alongside Roche.
additionally the FDA update expected can green light the MBc phase 3, trial.
We do not know if there are negotiations with other pharma or not.
however, again rewinding the history. It was Pfizer that requested the Aware-1 trial.
and, the mutiple cohurt trials with Roche , for G.I. Cancers.
lead being the pancreatic, probably second in line the anal cancer, that presently has zero standard of care on the market.
onc has come a very long way since 2017.
Share price does not reflect that.
obviously.
why?
Many theories. Those on here pointing to chrypto as an investment, a great example of mindset.
People continue to value an investment as the trading price.
i guess if you are buying & selling, that is a fair measure.
Should Onc sucseed,...& they are trying very hard & Pela gets to market
onc will become a multi billion company
Reminder , since 2017, they have added 2 businesses focused board members.
created a science advisory committee.
including assets from world cancer leading agencies.
is this Stockhouse site, worthless?
According to the most worthless poster on here....again, well over 200 posts.
Not one solid piece of data, or information.
Has everything I ever posted been 100% accurate?
I am a professional speaker , presenter etc. I try real hard to investigate prior to posting.
Yet, a few dates have been off etc.
stepping way back, we need to look at motivation.
i am a shareholder & belive Onc does have the answer.**
my motivation? Need to counter those working real hard to damage the credibility of not only Onc, but also this site.
** it was discovered & proven countless times. Pelareorep only multiplies in tumour environment.
can be given systemically via I.V. Pela will find the tumours.
regretably the mistake was assuming Pela could act alone.
since 2017, all focus has been on co- therapy.
The most recent results have been great.
Stay tuned.
the recent CGaR announcement, is not a small update.